| Title |
Safety and efficacy of alternate-day corticosteroid treatment as adjunctive therapy for rheumatoid arthritis: a comparative study
|
|---|---|
| Published in |
Clinical Rheumatology, March 2018
|
| DOI | 10.1007/s10067-018-4073-7 |
| Pubmed ID | |
| Authors |
Masei Suda, Sachiko Ohde, Tokutaro Tsuda, Mitsumasa Kishimoto, Masato Okada |
| Abstract |
Corticosteroids (CSs), used to treat rheumatoid arthritis (RA), confer a risk of adverse events (AEs). This study investigated the safety and efficacy of alternate-day (QOD) CS therapy for RA. All patients (> 18 years) who started oral CS therapy for RA, between 2005 and 2014, at our hospital were retrospectively analysed. The patients were divided into the daily (QD) and QOD CS therapy groups to investigate the rates of CS-related major AEs (infection, diabetes, hypertension, cardiovascular events and fragility fractures) within the first year of treatment. The number of patients free from CS treatment at 1 year and the mean decreases in C-reactive protein (CRP) levels at 1 month were also investigated. In total, 138 patients were analysed (QD group, 68; QOD group, 70). The maximum daily CS dose was not significantly different between the two groups, but the annual cumulative dose was significantly lower in the QOD group (P < 0.01). The infection rate was significantly lower in the QOD group (24.3%) than in the QD group (50.0%; P < 0.01), whereas the other AE rates were similar between the groups. The CS-free rate at 1 year was significantly higher in the QOD group (58.6%) than in the QD group (26.5%; P < 0.01). The mean CRP decreases over 1 month of CS therapy were not significantly different between the groups. QOD CS treatment leads to a lower infection rate and less CS dependence than does daily treatment; both RA treatments are equally effective. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 43 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 14% |
| Researcher | 5 | 12% |
| Lecturer | 5 | 12% |
| Student > Doctoral Student | 3 | 7% |
| Student > Bachelor | 2 | 5% |
| Other | 7 | 16% |
| Unknown | 15 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 42% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Computer Science | 1 | 2% |
| Nursing and Health Professions | 1 | 2% |
| Other | 2 | 5% |
| Unknown | 19 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 April 2018.
All research outputs
#18,604,390
of 23,045,021 outputs
Outputs from Clinical Rheumatology
#2,364
of 3,043 outputs
Outputs of similar age
#256,689
of 330,401 outputs
Outputs of similar age from Clinical Rheumatology
#42
of 67 outputs
Altmetric has tracked 23,045,021 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,043 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 12th percentile – i.e., 12% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,401 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.